REVIEW article

Front. Pharmacol.

Sec. Pharmacology of Ion Channels and Channelopathies

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1580086

This article is part of the Research TopicAdvanced Methodologies For Studying Function And Therapeutic Modulation of Ion Channels and Transporter ProteinsView all 4 articles

Exploring the ER Channel Protein Sec61: Recent Advances in Pathophysiological Significance and Novel Pharmacological Inhibitors

Provisionally accepted
  • 1Shandong Provincial Hospital, Shandong University;, Jinan, China
  • 2Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, China

The final, formatted version of the article will be published soon.

The Sec61 complex, which is located on the membrane of the mammalian endoplasmic reticulum (ER), serves as a pivotal component of protein transport channels. It plays a central role in the transport of nascent peptides and precursor peptides to the ER. This process includes the directed movement of precursor peptides to the ER membrane and the opening of the Sec61 transduction channel for translocation. The Sec61 channel not only plays a key role in transporting peptides into cells but also acts as a passive ER Ca2+ leak channel. In addition, the mutation, amplification and overexpression of Sec genes are closely related to the development of various genetic diseases and cancers. Over the past few decades, studies have elucidated the function of the Sec61 protein in the pathogenesis of diseases such as cancer, and Sec61 inhibitors have been developed for their treatment. This review describes the structure of Sec61 and its function in transporting ER transmembrane proteins and further summarizes the role of this gene in disease and recent advancements in Sec61 inhibitors. This study provides novel insights into the involvement of Sec61 in disease etiology and lays the groundwork for future treatment modalities targeting this pivotal protein complex.

Keywords: Sec61, Endoplasmic Reticulum, genetic disease, tumor, inhibitor

Received: 20 Feb 2025; Accepted: 22 May 2025.

Copyright: © 2025 辛, Peiyuan, yin and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Shanshan Shao, Shandong Provincial Hospital, Shandong University;, Jinan, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.